Abstract
Abstract In recent years, the venue of over-the-counter testing has advanced to the concept of direct access testing (DAT). Convenience, rapid turnaround, cost, and anonymity are some of the factors contributing to the increased interest in DAT. The negative aspects of DAT are numerous and are centered in the legal issues, physicians' acceptance, testing laboratory requirements, marketing and advertising, and the role of regulators. Direct access screening tests for infectious diseases generate a number of public health concerns, including ethics, follow-up, and contacts. Insurance and the added costs for retesting are additional factors to be addressed as the demand and availability of DAT grows.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
